Oruka Therapeutics (ORKA) Set to Announce Earnings on Wednesday

Oruka Therapeutics (NASDAQ:ORKA) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.5996) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, analysts expect Oruka Therapeutics to post ($2.42) EPS for the current fiscal year and ($2.93) EPS for the next fiscal year.

Oruka Therapeutics Stock Up 1.0%

ORKA opened at $100.55 on Wednesday. The business’s fifty day simple moving average is $88.17 and its 200 day simple moving average is $69.56. Oruka Therapeutics has a 52 week low of $25.23 and a 52 week high of $115.51. The stock has a market cap of $6.66 billion, a PE ratio of -49.53 and a beta of -0.34.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $74.81, for a total transaction of $523,670.00. Following the completion of the sale, the insider directly owned 31,771 shares in the company, valued at $2,376,788.51. This represents a 18.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $80.60, for a total value of $805,919.40. Following the transaction, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 179,950 shares of company stock valued at $16,492,680 over the last three months. Insiders own 23.49% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ORKA shares. Wedbush reiterated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 26th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.